Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/apt.15036 | DOI Listing |
Aliment Pharmacol Ther
November 2023
Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Health Sci Rep
March 2020
Department of Gastroenterology, Hepatopancreatology, and Digestive Oncology CUB Hôpital Erasme, Université Libre de Bruxelles Brussels Belgium.
Background: Alcohol-related liver disease (ALD) represents a major cause of death worldwide, and unfortunately, most patients are diagnosed at an advanced stage of the disease, which is related to poorer outcomes. Liver biopsy has historically been the gold standard for identifying advanced hepatic fibrosis, but this approach has several limitations, including invasiveness, low applicability, sampling variability, and cost.
Main Text: In order to detect earlier features of advanced liver fibrosis, surrogate biomarkers and techniques have been developed.
Aliment Pharmacol Ther
December 2018
Walter Reed National Military Medical Center, Bethesda, Maryland.
Over the past decade, there has been a renewed enthusiasm to develop noninvasive serum markers or tests to assess the presence and severity of fibrosis in chronic liver disease. Although a single marker or test has lacked the necessary accuracy to predict fibrosis, different combinations of these markers or tests have shown encouraging results. However, inter-laboratory variability and inconsistent results with liver diseases of varying etiologies have made it difficult to assess the reliability of these markers in clinical practice.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!